Implications of all the available evidence
RVF
A vaccine for use against RVF in humans remains an urgent unmet need. ChAdOx1 has been shown to be a scalable vaccine platform for COVID-19, but this is the first use of the platform for RVF in humans. ChAdOx1 RVF was well tolerated and generated strong humoral and cellular immune responses. Further evaluation of the vaccine in populations at most risk for RVF is warranted.